Hepion Pharmaceuticals to Participate in the ThinkEquity Conference

Rhea-AI Summary

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) announced that CEO Robert Foster will present at the ThinkEquity Conference in New York City on October 26, 2022, at 1:30 p.m. ET. The presentation will be live-streamed and archived on their website. Hepion's lead drug candidate, rencofilstat, targets non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). It has received Fast Track and Orphan Drug designations from the FDA, demonstrating its potential in treating liver diseases. The company utilizes its proprietary AI-POWR™ platform to enhance drug response insights.

EDISON, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, announced that its CEO, Robert Foster, PharmD, PhD, will present at the ThinkEquity Conference in New York City on October 26, 2022, at 1:30 p.m. Eastern Time.

The presentation will be broadcast live and archived on the Company's website at www.hepionpharma.com under "Events" in the Investors section.

About Hepion Pharmaceuticals

The Company's lead drug candidate, rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat is currently in clinical-phase development for the treatment of NASH, with the potential to play an important role in the overall treatment of liver disease - from triggering events through to end-stage disease. Rencofilstat has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards HBV, HCV, and HDV through several mechanisms, in nonclinical studies. In November 2021, the U.S. Food and Drug Administration (“FDA”) granted Fast Track designation for rencofilstat for the treatment of NASH. That was followed in June 2022 by the FDA’s granting of Orphan Drug designation to rencofilstat for the treatment of HCC.

Hepion has created a proprietary AI platform, called AI-POWR™, which stands for Artificial Intelligence - Precision Medicine; Omics (including genomics, proteomics, metabolomics, transcriptomics, and lipidomics); World database access; and Response and clinical outcomes. Hepion intends to use AI-POWR™ to help identify which NASH patients will best respond to rencofilstat, potentially shortening development timelines and increasing the delta between placebo and treatment groups. In addition to using AI-POWR™ to drive its ongoing NASH clinical development program, Hepion intends to use the platform to identify additional potential indications for rencofilstat to expand the company's footprint in the cyclophilin inhibition therapeutic space.

For further information, please contact:

Stephen Kilmer
Hepion Pharmaceuticals Investor Relations
Direct: (646) 274-3580
skilmer@hepionpharma.com  

FAQ

What is the date and time of Hepion Pharmaceuticals' presentation at the ThinkEquity Conference?

Hepion Pharmaceuticals will present on October 26, 2022, at 1:30 p.m. Eastern Time.

Where can I watch Hepion Pharmaceuticals' presentation?

The presentation will be broadcast live and archived on Hepion Pharmaceuticals' website under the 'Events' section.

What is rencofilstat and what diseases does it target?

Rencofilstat is Hepion's lead drug candidate targeting non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).

What designations has rencofilstat received from the FDA?

Rencofilstat has received Fast Track designation for NASH and Orphan Drug designation for HCC.

What is the purpose of the AI-POWR™ platform developed by Hepion?

The AI-POWR™ platform is designed to identify which NASH patients will respond best to rencofilstat, aiming to improve drug development timelines.